Connect with us

Technology

Juniper Biologics Expands Distribution Rights for Caris Life Sciences’ Molecular Profiling in the Middle East and Africa

Published

on

SINGAPORE, June 23, 2024 /PRNewswire/ — Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)’ solid tumour molecular profiling services in the Middle East and Africa (MEA). Caris is the leading next-generation AI TechBio company and precision medicine pioneer. This expansion follows the initial January 2023 distribution rights partnership with Caris for the same services in Southeast Asia (SEA). Juniper is now poised to offer Caris’ advanced solid tumour molecular profiling services across a broader region, enhancing patient access to personalised treatment options.

Caris’ best-in-class molecular profiling, combined with proprietary artificial intelligence, provides more precise and individualized cancer treatments. This profiling approach assesses DNA, RNA, and proteins, revealing a molecular blueprint that identifies treatment options specific to each patient’s cancer. Caris has developed the world’s largest and most informative platform for cancer analysis, featuring the most advanced tumour profiling available, including Whole Exome and Whole Transcriptome Sequencing across over 23,000 genes. By analysing biomarkers found in tumours, Caris helps healthcare providers make informed choices for personalised care.

Juniper Biologics is committed to driving positive change in the pharmaceutical industry on a global scale. Aligned with its mission to deliver transformative therapies through bold scientific innovation, Juniper’s collaboration with Caris will enhance access to quality treatments for patient communities in the Middle East and Africa. Juniper continues to pursue impactful partnerships aimed at uplifting communities and individuals, especially in underserved regions where access to advanced therapies is limited.

Raman Singh, Founder and Chief Executive Officer (CEO) of Juniper Biologics, spoke on the successful acquisition: “Caris molecular profiling bridges the gap between tumour biology and cancer treatments, guiding precision medicine through personalised treatment selection for physicians and their patients. Our exclusive partnership with Caris Life Sciences to distribute this service in the Middle East and Africa will significantly empower healthcare professionals to make informed decisions for their patients. This service enables oncologists to recommend highly personalised treatments that specifically target a patient’s cancer, thereby improving and expanding their care options. This targeted approach offers patients, particularly those with rare or aggressive cancers, an improved quality of life.”

“Caris is pleased to expand the distribution of our molecular profiling services in the Middle East and Africa through our partnership with Juniper Biologics,” said Caris President David Spetzler, MS, PhD, MBA. “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.”

This partnership marks a significant milestone in expanding access to personalised medicine and advanced cancer treatment technologies in the Middle East and Africa.

About Juniper Biologics

Backed by The Sylvan Group, Juniper Biologics is a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients, by building a growing presence in Oncology and Oncology Supportive Care, Rare/Orphan Diseases and Gene Therapy. It was founded on a vision to provide treatments for unmet medical needs focused on specialist therapy areas in which it can make the most difference. Through bold and transformative science, Juniper Biologics is committed to creating possibilities that have the potential to become the next generation of life-changing medicines for patient communities in China, Japan, Asia, Australia, New Zealand, Middle East, and Africa.

Website: https://www.juniperbiologics.com/

LinkedIn: https://www.linkedin.com/company/juniper-biologics

About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyse and unravel the molecular complexity of disease. This convergence of sequencing power, big data, and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection, and drug development.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia, and other international markets. To learn more, please visit CarisLifeSciences.com.

 

View original content:https://www.prnewswire.co.uk/news-releases/juniper-biologics-expands-distribution-rights-for-caris-life-sciences-molecular-profiling-in-the-middle-east-and-africa-302179643.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Ample Transfers Receives In-Principle Approval from MAS to Expand Regulated Payment Services in Singapore

Published

on

By

Ample Transfers plans to broaden digital payment capabilities following in-principle approval from the Monetary Authority of Singapore.

SINGAPORE, April 14, 2025 /PRNewswire/ — Ample Transfers, a Singapore-based provider of remittance and money-changing services established in 1998, has received in-principle approval from the Monetary Authority of Singapore (MAS) to expand its scope of regulated payment services under the Payment Services Act 2019.

The approval, part of a licence variation application, allows Ample Transfers to work towards offering four additional regulated services, subject to the fulfilment of conditions set out by MAS:

Account issuance serviceDomestic money transfer serviceMerchant acquisition serviceE-money issuance service

Ample Transfers is currently licensed to provide cross-border money transfer and money-changing services in Singapore.

This milestone positions Ample as one of the few Singapore-based players bridging the physical and digital remittance experience. If fully approved, it would enable Ample Transfers to extend its digital payment solutions to serve its core customer base better while continuing to build on its longstanding community presence. The company’s recent launch of remit.ai, an app-less, chat-driven service available at https://www.remit.ai/, complements its established retail footprint—reinforcing its unique approach to accessibility and trust in financial services.

Singapore’s payments ecosystem is evolving rapidly, and so are we,” said Matthew Yap, CEO of Ample Transfers. This in-principle approval reflects the growth journey we’ve shared with the communities we serve. We remain grounded in the needs of everyday people while building for the future with new tools and technologies.”

Looking ahead, Ample Transfers aims to deepen its commitment to financial inclusion, offering customers even more convenient and secure ways to move money, both online and over the counter.

About the IPA from the Monetary Authority of Singapore

An in-principle approval (IPA) in respect of a licence variation application reflects MAS’s view that the applicant’s licence variation application may be approved upon the fulfilment of specified conditions and provided there are no material adverse developments affecting the applicant. An IPA does not constitute an approval for the Company to provide Account Issuance, Domestic Money Transfer, Merchant Acquisition and E-Money Issuance services at this juncture. MAS reserves the right to rescind the IPA in circumstances where it considers appropriate.

For media and partnership enquiries:

Qing Yuan CHANG
Head of Partnerships, Ample Transfers
qingyuan@ampletransfers.com 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/ample-transfers-receives-in-principle-approval-from-mas-to-expand-regulated-payment-services-in-singapore-302427082.html

SOURCE Ample Transfers

Continue Reading

Technology

Aiper Secures Strategic Investment from Fluidra to Accelerate Global Growth in the Pool Industry

Published

on

By

The partnership and $100 million investment positions Aiper to scale operations and solidify its role as a leading player in smart pool cleaning technology by uniting complementary strengths to deliver enhanced solutions to a broader customer base

BARCELONA, Spain, April 14, 2025 /PRNewswire/ —  Aiper, a global leading player in cordless robotic pool cleaning, announces an agreement for a new financing round totaling $100 million. Led by Fluidra, a prominent force in the global pool industry, this round marks the beginning of a strategic alliance between the two companies.

As part of this collaboration, Aiper and Fluidra will combine their complementary strengths to grow the largely unpenetrated pool cleaning market, accelerate innovation, reach more customers, and confirm Aiper as a leading player in the industry.

Partnering with a leader in the Professional Pool Channel

With over 50 years of experience, Fluidra is a global leader in pool equipment and connected solutions in the pool and wellness sector. Its portfolio of trusted brands, such as AstralPool, Zodiac, Jandy, and Polaris, are well-established across Europe, North America, Latin America and APAC, serving both residential and commercial pool segments.

An opportunity for growth, this strategic collaboration enables Aiper to broaden its consumer base – helping to achieve a full omnichannel presence – and receive support for its European distribution network, patented technologies, and extensive industry resources. Through this partnership, Fluidra will also be in a position to expand its product range within the professional channel.

As a leading brand in online direct-to-consumer channels, Aiper is now available in over 7,000 stores through key retailers across Europe and North America. Support from this partnership with Fluidra will help drive the company’s global expansion.

Redefining the Robotic Pool Cleaning Ecosystem

The robotic pool cleaner market is entering a new era. Aiper, leveraging proprietary cordless technology, AI-driven capabilities, and intelligent water quality management, has continued to demonstrate strong operational excellence – thus solidifying the company as a leading force in the industry. The partnership between Aiper and Fluidra will redefine the global robotic pool cleaner market ushering in a more dynamic, competitive landscape. By combining cutting-edge technology, complementary distribution networks, and operational efficiency, this alliance will transform the industry’s ecosystem, accelerating a transition to a market that is scalable, brand and innovation-driven, and globally unified to reach ever more consumers and ultimately shape the future of the industry.

Pioneering the Future of the Smart Yard Globally

Looking ahead, Aiper is setting its sights on the broader smart yard ecosystem. With this funding and partnership in place, the company is well-positioned to pioneer a new generation of product solutions that redefine modern pool and yard care.

“This is an exciting moment for Aiper,” said Richard Wang, Aiper Founder and CEO. “Joining forces with Fluidra, a global industry leader, gives us an incredible opportunity to accelerate our innovation and growth. We share a passion for pushing the boundaries of intelligent pool cleaning and, together, we’re poised to redefine what’s possible. With Fluidra’s global reach and capabilities, we’re more confident than ever in our ability to deliver smarter, more efficient pool cleaning and yard solutions. Currently, we’re focused on deepening our presence in Europe and North America while actively expanding into emerging markets across the Middle East, Latin America, and Asia-Pacific. Our goal is to build a truly global smart yard ecosystem.”

For more information about Aiper visit Aiper.com and follow Aiper on LinkedIn, Facebook, Instagram, TikTok, and X.

View original content:https://www.prnewswire.com/apac/news-releases/aiper-secures-strategic-investment-from-fluidra-to-accelerate-global-growth-in-the-pool-industry-302427138.html

SOURCE Aiper

Continue Reading

Technology

Fangzhou Presents AI-Driven Healthcare Ecosystem at Guangzhou Biotech Innovation Salon

Published

on

By

GUANGZHOU, China, April 13, 2025 /PRNewswire/ — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leading Internet healthcare solution provider, participated in the “AI Empowers Biopharma” exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare.

Guo Zhi, Senior Vice President of Technology of Fangzhou, shared during the panel: “At Fangzhou, we’ve systematically addressed the core challenges in healthcare delivery by pioneering our AI + H2H Smart Healthcare Ecosystem. This innovative model extends critical services — including chronic disease management, patient education, and medication delivery — directly into patients’ homes, significantly improving care accessibility and timeliness while enhancing the overall treatment experience.”

Mitigate AI hallucinations

The Company also unveiled its proprietary framework to mitigate AI hallucinations in medical applications, combining a self-developed training platform with a professional medical knowledge base and data sandbox. This approach powers Fangzhou’s “AI Agent Matrix,” featuring round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation, collectively enhancing care accessibility while reducing operational costs.

Blueprint for Vertical AI Leadership

Moving forward, Fangzhou will intensify its focus on the vertical field of AI + Healthcare, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. The Company will seize opportunities like this panel to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare.

AI-Powered Growth Strategy

Fangzhou’s growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen the Company’s technological leadership, and fast-track the market adoption of its innovations — all with the goal of delivering superior care experiences and enhanced solutions for patients and users.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.

About the “AI Empowers Biopharma” Exchange Panel

Guangzhou Development District is accelerating its push to become a biopharma innovation leader, with this “AI Empowers Biopharma” exchange panel spotlighting AI-driven antibody research, quantum computing for drug development, and smart healthcare ecosystems.

Media Contact

For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com 

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

View original content to download multimedia:https://www.prnewswire.com/news-releases/fangzhou-presents-ai-driven-healthcare-ecosystem-at-guangzhou-biotech-innovation-salon-302427208.html

SOURCE Fangzhou Inc.

Continue Reading

Trending